
|Videos|November 14, 2017
Dr. Chari on Comparing Agents in Multiple Myeloma
Author(s)Ajai Chari, MD, PhD
Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses comparing agents in multiple myeloma.
Advertisement
Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses comparing agents in multiple myeloma.
The median overall survival of multiple myeloma has been on the rise, in part due to the plethora of novel agents that have emerged.
With 9 drugs approved in the last decade, choosing among the various regimens and combinations can be overwhelming, says Chari. Comparing these agents though is not so simple, as there are many variables to any given trial.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5



































